2. Cell Cycle/DNA Damage Cytoskeleton Apoptosis
  3. Microtubule/Tubulin Apoptosis Caspase
  4. BKT300

BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML.

For research use only. We do not sell to patients.

BKT300

BKT300 Chemical Structure

CAS No. : 2551033-16-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BKT300 Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML[1].

IC50 & Target[1]

PRC1

 

Caspase-3

 

In Vitro

BKT300 binds recombinant PRC1 with Kd values of 28.3 nM (SPR assay) and 104 nM (MST assay)[1].
BKT300 (31.25-5000 nM; 3 h) inhibits migration of U937 and Jurkat cells toward CXCL12, and migration of THP-1 cells toward MCP-1[1].
BKT300 (62.5-500 nM; 24 h) dose-dependently inhibits actin filament formation in U937 cells, but not in normal peripheral blood mononuclear cells (PBMCs)[1].
BKT300 (1 µM; 24 h) disrupts microtubule organization and formation in U937 cells[1].
BKT300 (7.8-5000 nM; 2-24 h) induces G2/M arrest and cell death in U937, MV4-11, OCI-AML-2, OCI-AML-3, Molm14, and Marimo AML cells[1].
BKT300 (3.9-1000 nM; 24 h) induces dose-dependent apoptosis in U937 cells, accompanied by elevated cleaved caspase-3 expression[1].
BKT300 (50-1000 nM; 24 hours) downregulates CDC25C, upregulates p21, and induces dose/time-dependent PRC1 phosphorylation at T481 in U937 and MV4-11 cells[1].
BKT300 (31.2-500 nM; 24 h) increases pPRC1 (T481) levels in U937 cells but not in normal PBMCs[1].
BKT300 (24 h) inhibits OCI-AML-3, Marimo, OCI-AML-2, MOLM-14, U937, K562, MV4-11 and HL-60 cells with IC50s of 107, 135, 120, 122, 27, 98, 98, and 110 nM, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BKT300 Related Antibodies

Cell Cycle Analysis[1]

Cell Line: U937 cells
Concentration: 19.5, 39, 62.5, 78, 156, 313, 625, 1250, 2500, 5000 nM
Incubation Time: 24 h; 2, 4, 6, 8, 24 h (at 62.5 nM)
Result: Induced G2/M cell cycle arrest in U937 cells, in a dose- and time-dependent manner.
Induced cell death in U937 cells at 62.5 nM.

Cell Cycle Analysis[1]

Cell Line: OCI-AML-2, OCIAML-3, Molm14, Marimo
Concentration: 250 nM
Incubation Time: 24 h
Result: Induced G2/M cell cycle arrest in all tested cells.

Apoptosis Analysis[1]

Cell Line: U937 cells
Concentration: 3.9, 7.8, 15.6, 31.25, 62.5, 125, 250, 500, 1000 nM
Incubation Time: 24 h
Result: Increased apoptotic cells in U937 cells in a dose-dependent manner.

Cell Migration Assay [1]

Cell Line: U937, Jurkat, and THP-1 leukemic cells
Concentration: 31.25, 62.5, 125, 250, 500, 1000 nM (U937 and THP1 cells); 125, 250, 500, 1000, 5000 nM (Jurkat cells)
Incubation Time: 3 h
Result: Significantly inhibited the migration of U937 cells and Jurkat cells toward CXCL12 in a dose-dependent manner.
Inhibited the migration of AML THP-1 cells toward monocyte chemotactic protein-1 (MCP-1) in a dose-dependent manner.

Western Blot Analysis[1]

Cell Line: U937, REH, NB4, MV4-11cells
Concentration: 50, 100, 1000 nM (U937 cells); 1000 nM (REH, NB4, MV4-11cells)
Incubation Time: 24 h
Result: Increased cleaved caspase-3 levels in U937 cells in a dose-dependent manner.
Increased cleaved caspase-3 levels in U937, REH, NB4, MV4-11cells at 1000 nM.

Western Blot Analysis[1]

Cell Line: U937, MV4-11 leukemic cell lines
Concentration: 50 nM, 100 nM, 1000 nM (24 h CDC25C/p21); 100 nM, 500 nM, 1000 nM (24 h pPRC1); 1000 nM (pPRC1 time course)
Incubation Time: 24 h (CDC25C/p21, pPRC1 dose-response); 4 h, 24 h (pPRC1 time course)
Result: Downregulated CDC25C and upregulated p21 in U937/MV4-11 cells without affecting CDC2/cyclin B1.
Induced a dose-dependent increase in PRC1 phosphorylation at T481 within 4 h, peaking at 24 h, without altering total PRC1 levels.

Immunofluorescence[1]

Cell Line: U937 cells, normal PBMCs
Concentration: 31.2, 62.5, 125, 250, 500 nM
Incubation Time: 24 h
Result: Induced a dose-dependent increase in pPRC1 (T481) levels in U937 cells.
Had no effect on pPRC1 or total PRC1 levels in normal PBMCs.
In Vivo

BKT300 (1-2.5 mg/mouse; s.c.; once daily from day 3 to day 7 ) inhibits tumor growth in the U937 xenograft mouse model[1].
BKT300 (2.5 mg/mouse; s.c.;twice daily from day 10 to day 12) inhibits tumor growth and induces tumor regression in the U937 xenograft mouse model[1].
BKT300 (2.5 mg/mouse; s.c.; on day 12 to day 16 and day 19 to day 20) reduces AML cell levels in blood and bone marrow in the MV4-11 intravenous xenograft mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD scid gamma (NSG) mice (6-8-week-old) subcutaneously injected with U937 cells[1]
Dosage: 1, 1.5, 2, 2.5 mg/mouse
Administration: s.c.; once daily from day 3 to day 7
Result: Achieved 98% tumor growth inhibition, with 6/7 treated mice exhibiting complete tumor growth inhibition by day 11.
Induced apoptosis of tumor cells.
Decreased CDC25C and increased pPRC1 T481 expression in the tumors.
Animal Model: NOD scid gamma (NSG) mice (6-8-week-old) subcutaneously injected with U937 cells[1]
Dosage: 2.5 mg/mouse
Administration: s.c.; twice daily from day 10 to day 12
Result: Reached 95.9% tumor growth inhibition and 89.4% tumor regression by day 17.
Showed no effect on body weight.
Animal Model: NOD scid gamma (NSG) mice (6-8-week-old) intravenously injected with MV4-11 cells[1]
Dosage: 2.5 mg/mouse
Administration: s.c.; on day 12 to day 16 and day 19 to day 20
Result: Reduced the percentage of AML cells in the blood by 74.8% and in bone marrow by 72%.
Increased the number of normal mouse cells in the bone marrow by 2-fold and in blood by 7-fold compared to control mice.
Molecular Weight

399.44

Formula

C22H25NO6
CAS No.
SMILES

O=C1NC2=C(C(O)=C1CCCCC)C=C(OC)C=C2OC3=CC=C(C=C3OC)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BKT300 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BKT3002551033-16-8BKT 300BKT-300Microtubule/TubulinApoptosisCaspaseProtein regulator of cytokinesis 1actinapoptosisAML cellsmitotic catastrophecaspase-3 pathwaymouse xenograft AML modelsmicrotubulePRC1G2/M cell cycle arrestInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BKT300
Cat. No.:
HY-179466
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.